Dawei Zhang

Title: Dawei Zhang - Innovator in Non-Opioid Pain Therapeutics

Introduction

Dawei Zhang is a prominent inventor based in Cambridge, MA, known for his groundbreaking work in the field of pain therapeutics. His innovative approach focuses on developing non-opioid solutions to manage pain, addressing a critical need in modern medicine.

Latest Patents

Zhang holds a patent for "Therapeutic compositions for treating pain via multiple targets." This invention introduces non-opioid pain therapeutic compositions that utilize an antisense oligonucleotide (ASO) targeting specific NaV channel mRNA. The ASO hybridizes to its target RNA, forming a duplex that recruits RNase H to degrade the RNA. This process downregulates NaV channel synthesis, effectively inhibiting the neuron's ability to contribute to pain perception. The ASO can be designed as a gapmer, featuring a central DNA segment flanked by modified RNA wings. In vitro studies show that when delivered to dorsal root ganglion (DRG) neurons, the composition results in a dose-dependent knockdown of NaV1.7, NaV1.8, or NaV1.9.

Career Highlights

Zhang's career is marked by his dedication to advancing pain management therapies. His innovative work has positioned him as a key figure in the development of non-opioid treatments, which are crucial in combating the opioid crisis.

Collaborations

Zhang collaborates with talented individuals such as Caitlin Lewarch and Pin Liu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Dawei Zhang's contributions to the field of pain therapeutics exemplify the potential of innovative approaches in medicine. His work not only addresses the urgent need for non-opioid pain management solutions but also paves the way for future advancements in therapeutic compositions.